We assessed the synergistic effect of the combination of SRE and anti-PD-1 antibodies using humanized PD-1 knockin mice and humanized PD-L1 MC38 tumor cells and successfully established a CRC immunotherapy. This evidence concerns the gene CD274 and neoplasm.